KRAS-mutated

Clinical trials for KRAS-mutated explained in plain language.

Never miss a new study

Get alerted when new KRAS-mutated trials appear

Sign up with your email to follow new studies for KRAS-mutated, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New drug combo takes aim at KRAS-Mutant lung cancer

Disease control Recruiting now

This Phase 2 trial tests whether combining two oral drugs, luvometinib and anlotinib, can shrink tumors in people with KRAS-mutated non-small cell lung cancer that has spread and stopped responding to prior treatment. About 48 adults will receive different dose combinations. The …

Matched conditions: KRAS-MUTATED

Phase 2 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control

Last updated Sep 04, 2026 00:00 UTC

KRAS-mutated

Get alerted when new KRAS-mutated trials appear

New drug combo takes aim at KRAS-Mutant lung cancer